Neurona Therapeutics Launches With .5 Million in Series A Funding to Repair Damaged …

Company Combines Leaders in Fields of Neuroscience and Stem Cell Biology to Develop Cell Therapies With Broad Potential to Treat Neurological Disease SOUTH SAN FRANCISCO, CA–(Marketwired – December 01, 2015) – Neurona Therapeutics Inc., a biotechnology company focused on the transplantation of selected neurons to treat intractable neurological diseases, today announced its launch with a $23.5 million Series A financing led by The Column Group. Unlike more traditional therapeutic modalities such as small molecules or antibodies, Neurona is focused on unique compositions of cells that can be precisely targeted, integrated into damaged neural circuits, and provide activity-dependent regulation. “We believe there is an unprecedented opportunity to create a novel class of therapeutics with the potential to permanently repair dysfunctional neural circuits,” said Tim Kutzkey, interim Chief Executive Officer of Neurona…


Link to Full Article: Neurona Therapeutics Launches With .5 Million in Series A Funding to Repair Damaged …